37S Stock Chart & Stats
€0.13
<€0.01(1.53%)
At close: 4:00 PM EDT
€0.13
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.11 - €0.26
Previous CloseN/A
Volume0.00
Average Volume (3M)49.79K
Market Cap
€4.80M
Enterprise Value€3.44
Total Cash (Recent Filing)€3.50M
Total Debt (Recent Filing)€1.53M
Price to Earnings (P/E)―
Beta0.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,544,390
10 Day Avg. Volume123,515
30 Day Avg. Volume49,788
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.23
Price to Sales (P/S)0.43
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / Balance-sheet ResilienceVery low debt-to-equity (~0.07) gives Spineway durable financial flexibility while it scales commercialization and R&D. Conservative leverage reduces insolvency risk, supports ongoing investment in product development and market expansion without forcing near-term capital raises.
Revenue Growth And Gross Margin RecoveryConsistent top-line growth and a material gross margin rebound to ~26% show improving product-market fit and better pricing/production economics. This trend supports longer-term scalability: higher gross margins make sustainable profitability achievable as SG&A leverages revenue.
Operating Cash Flow Turned PositiveA shift to positive operating cash flow signals the core business is beginning to generate cash from operations. Durable OCF improvement reduces reliance on external financing, enabling reinvestment in sales/distribution and product improvements if managed alongside capex discipline.
Bears Say
Ongoing Net LossesA persistent net loss and roughly -18% net margin indicate the company has not yet converted revenue growth into sustainable profitability. Continued losses can constrain reinvestment, force dilutive capital raises, and limit ability to scale commercial operations long term.
Free Cash Flow Not Sustainably PositiveAlthough OCF turned positive, free cash flow remains essentially zero after investment needs. This structural weakens financial flexibility: capex and working-capital requirements can absorb cash, raising the likelihood of future financing if profitability improvements stall.
Negative Returns On Equity And Small ScaleNegative ROE shows the company’s capital base isn't yet generating investor returns, reflecting either margin shortfalls or limited scale. Small organizational size and negative ROE make competing with larger medtech peers and absorbing commercial fixed costs more difficult over the medium term.
Spineway SA News
37S FAQ
What was Spineway SA’s price range in the past 12 months?
Spineway SA lowest stock price was €0.11 and its highest was €0.26 in the past 12 months.
What is Spineway SA’s market cap?
Spineway SA’s market cap is €4.80M.
When is Spineway SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Spineway SA’s earnings last quarter?
Currently, no data Available
Is Spineway SA overvalued?
According to Wall Street analysts Spineway SA’s price is currently Overvalued.
Does Spineway SA pay dividends?
Spineway SA does not currently pay dividends.
What is Spineway SA’s EPS estimate?
Spineway SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spineway SA have?
Spineway SA has 35,544,390 shares outstanding.
What happened to Spineway SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Spineway SA?
Currently, no hedge funds are holding shares in DE:37S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spineway SA
Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion products, such as lumbar cage twin peaks tlif curved and oblique; motion preservation products; and biomaterials. It also exports its products. The company was incorporated in 2005 and is headquartered in Ecully, France.